• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含载脂蛋白B的脂蛋白中的载脂蛋白C-III含量与血管蛋白聚糖双糖链蛋白聚糖的结合有关。

ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan.

作者信息

Olin-Lewis Katherine, Krauss Ronald M, La Belle Michael, Blanche Patricia J, Barrett P Hugh R, Wight Thomas N, Chait Alan

机构信息

Department of Medicine, University of Washington, Seattle, WA, USA.

出版信息

J Lipid Res. 2002 Nov;43(11):1969-77. doi: 10.1194/jlr.m200322-jlr200.

DOI:10.1194/jlr.m200322-jlr200
PMID:12401896
Abstract

Retention of apolipoprotein (apo)B and apoE-containing lipoproteins by extracellular vascular proteoglycans is critical in atherogenesis. Moreover, high circulating apoC-III levels are associated with increased atherosclerosis risk. To test whether apoC-III content of apoB-containing lipoproteins affects their ability to bind to the vascular proteoglycan biglycan, we evaluated the impact of apoC-III on the interaction of [(35)S]SO(4)-biglycan derived from cultured arterial smooth muscle cells with lipoproteins obtained from individuals across a spectrum of lipid concentrations. The extent of biglycan binding correlated positively with apoC-III levels within VLDL (r = 0.78, P < 0.01), IDL (r = 0.67, P < 0.01), and LDL (r = 0.52, P < 0.05). Moreover, the biglycan binding of VLDL, IDL, and LDL was reduced after depletion of apoC-III-containing lipoprotein particles in plasma by anti-apoC-III immunoaffinity chromatography. Since apoC-III does not bind biglycan directly, enhanced biglycan binding may result from a conformational change associated with increased apo C-III content by which apoB and/or apoE become more accessible to proteoglycans. This may be an intrinsic property of lipoproteins, since exogenous apoC-III enrichment of LDL and VLDL did not increase binding. ApoC-III content may thus be a marker for lipoproteins characterized as having an increased ability to bind proteoglycans.

摘要

细胞外血管蛋白聚糖对载脂蛋白(apo)B和含apoE脂蛋白的保留在动脉粥样硬化形成过程中至关重要。此外,循环中apoC-III水平升高与动脉粥样硬化风险增加相关。为了测试含apoB脂蛋白的apoC-III含量是否影响其与血管蛋白聚糖双糖链蛋白聚糖结合的能力,我们评估了apoC-III对来自培养的动脉平滑肌细胞的[(35)S]SO(4)-双糖链蛋白聚糖与从脂质浓度范围各异的个体获得的脂蛋白之间相互作用的影响。双糖链蛋白聚糖结合程度与极低密度脂蛋白(VLDL)(r = 0.78,P < 0.01)、中间密度脂蛋白(IDL)(r = 0.67,P < 0.01)和低密度脂蛋白(LDL)(r = 0.52,P < 0.05)中的apoC-III水平呈正相关。此外,通过抗apoC-III免疫亲和层析去除血浆中含apoC-III的脂蛋白颗粒后,VLDL、IDL和LDL与双糖链蛋白聚糖的结合减少。由于apoC-III不直接结合双糖链蛋白聚糖,增强的双糖链蛋白聚糖结合可能是由于与apoC-III含量增加相关的构象变化导致apoB和/或apoE更容易被蛋白聚糖识别。这可能是脂蛋白的固有特性,因为外源性apoC-III富集LDL和VLDL并未增加结合。因此,apoC-III含量可能是脂蛋白具有增加的与蛋白聚糖结合能力的一个标志物。

相似文献

1
ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan.含载脂蛋白B的脂蛋白中的载脂蛋白C-III含量与血管蛋白聚糖双糖链蛋白聚糖的结合有关。
J Lipid Res. 2002 Nov;43(11):1969-77. doi: 10.1194/jlr.m200322-jlr200.
2
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.高胆固醇血症和高甘油三酯血症中,由载脂蛋白E或载脂蛋白C-III的存在所定义的含载脂蛋白B的不同脂蛋白模式。
J Lipid Res. 2001 Aug;42(8):1239-49.
3
Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content.雌激素口服避孕药对由载脂蛋白E和C-III含量定义的脂蛋白B颗粒系统的影响。
J Lipid Res. 1999 Feb;40(2):202-12.
4
Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.载脂蛋白C-III的脂蛋白分布及其与富含甘油三酯的残余脂蛋白在血浆中存在的关系。
Metabolism. 2001 Jan;50(1):112-9. doi: 10.1053/meta.2001.19452.
5
Fat ingestion is associated with increased levels of apoC-III- and apoE-B-containing lipoprotein particles in humans.在人类中,脂肪摄入与含载脂蛋白C-III和载脂蛋白E-B的脂蛋白颗粒水平升高有关。
Eur J Clin Invest. 1997 Dec;27(12):1055-60. doi: 10.1046/j.1365-2362.1997.2350782.x.
6
Differential metabolism of human VLDL according to content of ApoE and ApoC-III.根据载脂蛋白E和载脂蛋白C-III含量对人极低密度脂蛋白进行差异代谢
Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1494-500. doi: 10.1161/hq0901.094489.
7
In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.正常血脂受试者中极低密度脂蛋白载脂蛋白B、CIII和E的体内代谢
Nutr Metab Cardiovasc Dis. 2006 Apr;16(3):215-21. doi: 10.1016/j.numecd.2005.06.004. Epub 2005 Nov 2.
8
Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde.心肌梗死风险不同的两个人群中载脂蛋白B和非载脂蛋白脂蛋白中的载脂蛋白C-III和E:ECTIM研究。心肌梗死病例对照研究。
J Lipid Res. 1996 Mar;37(3):508-17.
9
Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.极低密度脂蛋白、中间密度脂蛋白和低密度脂蛋白与人类动脉壁蛋白聚糖的相互作用。
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2507-14. doi: 10.1161/01.atv.17.11.2507.
10
Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.内脏肥胖中载脂蛋白B-100的动力学:与血浆载脂蛋白C-III浓度的关联
Metabolism. 2002 Aug;51(8):1041-6. doi: 10.1053/meta.2002.33339.

引用本文的文献

1
Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation.载脂蛋白C-III循环水平与炎症生物标志物之间的非甘油三酯依赖性关联。
Cardiovasc Diabetol. 2025 Jan 8;24(1):9. doi: 10.1186/s12933-024-02553-z.
2
Apolipoprotein B-containing lipoproteins in atherogenesis.动脉粥样硬化形成过程中含载脂蛋白B的脂蛋白
Nat Rev Cardiol. 2025 Jun;22(6):399-413. doi: 10.1038/s41569-024-01111-0. Epub 2025 Jan 2.
3
Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.
载脂蛋白C3在糖尿病心血管疾病风险和代谢紊乱中的多方面作用
Int J Mol Sci. 2024 Nov 27;25(23):12759. doi: 10.3390/ijms252312759.
4
Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review.动脉粥样硬化炎症靶向管理的最新进展:叙述性综述
Cardiol Ther. 2024 Sep;13(3):465-491. doi: 10.1007/s40119-024-00376-3. Epub 2024 Jul 20.
5
Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.载脂蛋白 CIII 的 O-糖基化与 2 型糖尿病的微血管和大血管并发症有关。
Int J Mol Sci. 2024 May 14;25(10):5365. doi: 10.3390/ijms25105365.
6
In the Beginning, Lipoproteins Cross the Endothelial Barrier.起初,脂蛋白穿过血管内皮屏障。
J Atheroscler Thromb. 2024 Jun 1;31(6):854-860. doi: 10.5551/jat.RV22017. Epub 2024 Apr 13.
7
Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.缩小血脂异常患者管理中的差距:通过载脂蛋白分析迈向心血管精准诊断。
Clin Proteomics. 2024 Mar 1;21(1):19. doi: 10.1186/s12014-024-09465-w.
8
A novel assay to measure low-density lipoproteins binding to proteoglycans.一种测量低密度脂蛋白与蛋白聚糖结合的新方法。
PLoS One. 2024 Jan 31;19(1):e0291632. doi: 10.1371/journal.pone.0291632. eCollection 2024.
9
Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.探索载脂蛋白 C-III:病理生理学和药理学相关性。
Cardiovasc Res. 2024 Feb 17;119(18):2843-2857. doi: 10.1093/cvr/cvad177.
10
Apolipoprotein C3: form begets function.载脂蛋白C3:形态决定功能。
J Lipid Res. 2024 Jan;65(1):100475. doi: 10.1016/j.jlr.2023.100475. Epub 2023 Nov 14.